180 related articles for article (PubMed ID: 11125949)
21. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
22. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
23. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
24. Soluble interleukin-2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma.
Sarandakou A; Poulakis N; Rizos D; Trakakis E; Phocas I
Anticancer Res; 1993; 13(1):173-5. PubMed ID: 8386493
[TBL] [Abstract][Full Text] [Related]
25. [The prognostic value of serum neuron specific enolase detection in small cell lung cancer].
Jin B; Zhao L; Zhou C
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Dec; 24(12):722-4. PubMed ID: 11930699
[TBL] [Abstract][Full Text] [Related]
26. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
27. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
28. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
30. [Progression from adenocarcinoma to small cell carcinoma of the prostate during endocrinotherapy: a case report].
Maeno A; Kamoto T; Kitamura K; Kanno T; Okuno H; Terai A; Kakehi Y; Terachi T; Ogawa O; Matsushiro H
Hinyokika Kiyo; 2001 Aug; 47(8):591-3. PubMed ID: 11579603
[TBL] [Abstract][Full Text] [Related]
31. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
32. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
33. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
34. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
35. [Small renal cell carcinoma of the prostate with cerebral metastasis].
Rivas Alonso A; Gómez Dorronsoro M; Valenti Ponsa C
Actas Urol Esp; 1996 Jun; 20(6):582-5. PubMed ID: 8928688
[TBL] [Abstract][Full Text] [Related]
36. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
37. Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center's experience.
Carranza OE; Castañón E; Abella LE; Zudaire ME; Castillo A; Arévalo E; Fusco JP; Zudaire JJ; Carías R; Cambeiro M; Martínez-Monge R; Gil-Bazo I
Clin Genitourin Cancer; 2013 Jun; 11(2):168-74. PubMed ID: 23146567
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer with small-cell morphology: an immunophenotypic subdivision.
Petraki C; Vaslamatzis M; Petraki K; Revelos K; Alevizopoulos N; Papanastasiou P; Gregorakis A
Scand J Urol Nephrol; 2005; 39(6):455-63. PubMed ID: 16303720
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature].
Wei ZF; Xu H; Wang H; Wei W; Cheng W; Zhou WQ; Ge JP; Zhang ZY; Gao JP; Yin HL
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):829-32. PubMed ID: 19947569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
